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Aims Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced
ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared
with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF.
We made indirect comparisons of the effects of LCZ696 with putative placebos.
Methods
and results
We used the treatment-armof the Studies OfLeftVentricular Dysfunction (SOLVD-T) as thereference trial forcomparison
of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity-
Alternative trial (CHARM-Alternative) as the reference trial for comparison of an ARB to placebo. The hazard ratio of
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LCZ696vs. aputativeplacebowasestimated through theproductof thehazardratioofLCZ696vs.enalapril (active-control)
and that of the historical active-control (enalapril or candesartan) vs. placebo. For the primary composite outcome of car-
diovascular death or heart failure hospitalization in PARADIGM-HF, the relative risk reduction with LCZ696 vs. a putative
placebo from SOLVD-T was 43% (95%CI 34–50%; P, 0.0001) with similarly large effects on cardiovascular death (34%,
21–44%; P, 0.0001) and heart failure hospitalization (49%, 39–58%; P, 0.0001). For all-cause mortality, the reduction
compared with a putative placebo was 28% (95%CI 15–39%; P, 0.0001). Putative placebo analyses based on CHARM-Al-
ternative gave relative risk reductions of 39% (95%CI 27–48%; P, 0.0001) for the composite outcome of cardiovascular
death or heart failure hospitalization, 32% (95%CI 16–45%; P, 0.0001) for cardiovascular death, 46% (33–56%;
P, 0.0001) for heart failure hospitalization, and 26% (95%CI 11–39%; P, 0.0001) for all-cause mortality.
Conclusion These indirect comparisons of LCZ696 with a putative placebo show that the strategy of combined angiotensin receptor
blockade and neprilysin inhibition led to striking reductions in cardiovascular and all-cause mortality, as well as heart
failure hospitalization. These benefits were obtained even though LCZ696 was added to comprehensive background
beta-blocker and mineralocorticoid receptor antagonist therapy.
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Introduction
Ethically, new antagonists of the renin–angiotensin system such as
angiotensin-receptor blockers (ARBs) and direct renin inhibitors have
to be tested in heart failure with reduced ejection fraction (HF-REF)
in active-controlled comparisons with an angiotensin converting
enzyme (ACE) inhibitor.1–4 Recently, LCZ696 which both blocks the
angiotensin II type 1 receptor as well as inhibits neprilysin, the enzyme
responsible fordegradationofnatriuretic andothervasoactivepeptides,
was alsocomparedwithenalapril inpatientswithHF-REF.5 LCZ696was
superior to enalapril, reducing the primary composite outcome of car-
diovascular death or heart failure hospitalization (and both components
of this composite), as well as all-cause mortality. Although active-
controlled trials such as this may be ethically mandated, clinicians and
regulators often want to know how the experimental therapy would
have performed had it been compared directly with placebo. Well-
developed statistical approaches allow such indirect comparisons to
be made, assuming that a comparison of the active-control (standard
therapy) andplacebo is available,which is thecase inHF-REF.6–8 Wede-
scribe putative placebo analyses for LCZ696 using both a placebo-
controlled ACE inhibitor and a similar ARB trial in HF-REF.
Methods
We used the treatment-arm of the Studies Of Left Ventricular Dysfunc-
tion (SOLVD-T) as the reference trial for comparison of an ACE inhibitor
to placebo.9 We used the Candesartan in Heart failure; Assessment
of Reduction in Mortality and morbidity-Alternative trial (CHARM-
Alternative) as the reference trial for comparison of an ARB to placebo.10
These are the only large randomized trials comparing a renin–angiotensin
system inhibitor to placebo in patients with predominantly New York
Heart Association (NYHA) Class II and III heart failure with a reduced ejec-
tion fraction and the only trials reporting long-term clinical outcomes. As
such, they are well suited for comparison with PARADIGM-HF.
SOLVD-T
Patients in NYHA functional class II– IV with an LVEF ≤ 35% were eligible
for SOLVD-T if aged ≤80 years and not treated with an ACE inhibitor.9
There were a number of exclusion criteria including a serum creatinine
.177 mmol/l (.2.0 mg/dL). Patients entered a single-blind run-in
period of 2–7 days treatment with enalapril 2.5 mg bid followed by a
period of 14–17 days treatment with placebo. Thereafter, the 2569
remaining patients were randomly assigned to enalapril titrated to a
target dose of 10 mg bid or matching placebo. The primary endpoint
was all-cause mortality and the mean follow-up was 41.4 months.
CHARM-alternative
Patients in NYHA functional class II– IV with an LVEF ≤ 40% were eligible
for CHARM-Alternative if not receiving an ACE inhibitor due to previous
intolerance.10 There were a number of exclusion criteria including a
serum creatinine ≥265 mmol/l (≥3.0 mg/dL). Patients received other
standard medical therapy including diuretics, beta-blockers, and spirono-
lactone. A total of 2028 patients were randomized to candesartan,
titrated as tolerated up to a maximum daily dose of 32 mg or matching
placebo. Therewasno run-in period. The primary endpoint was the com-
posite of cardiovascular mortality or heart failure hospitalization and the
median follow-up was 33.7 months.
PARADIGM-HF
Patients in NYHA functional class II– IV, previously treated with an ACE
inhibitor or ARB and with an LVEF ≤ 40% (changed to ≤35% by amend-
ment dated 15 December 2010), and a plasma B-type natriuretic peptide
(BNP) of at least 150 pg/mL [or N-terminal proBNP (NT-proBNP) of at
least 600 pg/mL] or a BNP of at least 100 pg/mL (or NT-proBNP of at
least 400 pg/mL) if hospitalized for heart failure within the last 12
months were eligible for PARADIGM-HF.5 Patients were required to
be treated with a beta-blocker if tolerated and mineralocorticoid recep-
tor antagonist (MRA) therapy was recommended in accordance with
major international guidelines. There were a number of exclusion criteria
including an estimated glomerular filtration rate (eGFR) , 30 mL/min/
1.73 m2 body-surface area. Patients entered a single-blind run-in period
of 2 weeks treatment with enalapril 10 mg bid followed by a period of
2–4 weeks treatment with LCZ696 100 mg twice daily, increasing to
200 mg twice daily. Thereafter, the 8442 remaining patients were ran-
domly assigned to LCZ696 200 mg bid or matching enalapril 10 mg bid.
The primary endpoint was cardiovascular death or heart failure hospital-
ization and the median follow-up was 27 months.
Figure 1 shows in schematic format the comparisons made. The hazard
ratioof LCZ696 vs. a putativeplacebowasestimated through theproduct
of the hazard ratio of LCZ696 vs. enalapril (active-control) and that of
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the historical active-control (enalapril or candesartan) vs. placebo with
the assumption that the hazard ratio in the active-control vs. placebo
is the same as would have been obtained had a placebo arm been possible
in the trial with LCZ696. The standard error, used in the derivation of
the 95% confidence interval of the product, is derived from the square
root of the sum of the two squared standard errors of the logarithmic
hazard ratios. The hazard ratio and its standard error of the logarithmic
hazard ratio for the active control vs. placebo are obtained from the pub-
lished historical data. The method used here was similar to that used in
Fisher, Gent, and Bu¨ller using odds ratios.8 In this analysis, we made the
assumption that the effect of LCZ696 compared with enalapril would
be the same as that of LCZ696 compared with candesartan.
Results
Table 1 provides a summary of patient characteristics and baseline
treatment in SOLVD-T, CHARM-Alternative, and PARADIGM-HF.
The subjects enrolled in PARADIGM-HF were similar to those
enrolled in SOLVD-T in terms of the age, sex, NYHA functional
class distribution, LVEF, and eGFR. Hypertension was more common
in PARADIGM-HF and prior myocardial infarction was more
common in SOLVD-T. Beta-blocker use was much more common,
and digoxin use less common, in PARADIGM-HF, compared with
SOLVD-T. Mineralocorticoid use was not reported in SOLVD-T.
The patients enrolled in PARADIGM-HF (and SOLVD-T) were
younger and less often female compared with those in CHARM-
Alternative. The NYHA class distribution was different with more
patients in NYHA class II in PARADIGM-HF (and SOLVD-T) and
fewer in NYHA class III and IV, than in CHARM-Alternative. Systolic
blood pressurewas lower in PARADIGM-HF (and SOLVD-T) than in
CHARM-Alternative. Beta-blocker and MRA use was more common
in PARADIGM-HF than in CHARM-Alternative.
Table 2 shows the number of events and event rates in the three
trials for the clinical outcomes of interest. Table 3 summarizes
the treatment effects for these outcomes of interest in the three
trials. In SOLVD-T and CHARM-Alternative, active therapy was
superior to placebo, leading to statistically significant risk-reductions
in the composite of cardiovascular death or heart failure hospitaliza-
tion (and heart failure hospitalization alone) with both treatments
tested. However, while the reductions in cardiovascular and all-cause
mortality with enalapril were statistically significant in SOLVD-T,
they werenot inCHARM-Alternative, althoughtheywerequalitatively
and quantitatively similar to SOLVD-T. In PARADIGM-HF, all out-
comeswere reducedsignificantlyby LCZ696comparedwithenalapril.
Figure 2A–D shows the putative placebo analyses for LCZ696.
For the primary composite outcome of cardiovascular death or
heart failure hospitalization in PARADIGM-HF, the relative risk re-
duction with LCZ696 vs. a putative placebo from SOLVD-T was
43% (95%CI 34–50%; P, 0.0001) with similarly large effects on car-
diovascular death (34%, 21–44%; P, 0.0001) and heart failure
hospitalization (49%, 39–58%; P, 0.0001). For all-cause mortality,
the reduction compared with a putative placebo was 28% (95%CI
16–39%; P, 0.0001). Qualitatively and quantitatively, very similar
effects were seen when LCZ696 was compared with a putative
placebo from CHARM-Alternative (Figure 2).
Using the analysis based on CHARM-Alternative, compared with
a putative placebo, LCZ696 would have avoided or postponed 71
composite cardiovascular death or heart failure hospitalization events,
31 cardiovascular deaths, 59 first heart failure hospitalizations, and
18 deaths from any cause per 1000 patient-years of treatment.
Discussion
Because it is unethical towithhold an ACE inhibitoror ARB inpatients
with HF-REF, LCZ696 could not be compared directly with placebo.
Therefore, we made indirect comparisons, using putative placebos.
Employing a standard statistical approach, we quantified the effect
Figure 1 Schematic of the trials and comparisons used in the putative placebo analysis. SOLVD-T ¼ treatment arm of the Studies Of Left Ven-
tricular Dysfunction (comparing enalapril with placebo). CHARM-Alternative ¼ Candesartan in Heart failure:Assessment of Reduction in Mortality
and morbidity-Alternative trial (comparing candesartan with placebo). PARADIGM-HF ¼ Prospective comparison of Angiotensin Receptor Nepri-
lysin inhibitor (ARNI) with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (comparing LCZ696 with enalapril). For
enalapril, solid arrows indicate directly performed comparison in the trials specified (direction of arrow indicates comparison of experimental treat-
ment to the reference treatment); the interrupted arrow indicates the indirect, putative, placebo comparison (direction of arrow indicates compari-
son of experimental treatment to the putative placebo). For candesartan, the figure structure is the same except that it is assumed that the
comparison in PARADIGM-HF was LCZ696 vs. candesartan (as opposed to enalapril in reality). The hazard ratios shown are those measured in
the trials specified; the indirectly calculated hazard ratios for LCZ696 against placebo are shown in Table 3. (a) Cardiovascular death or heart
failure hospitalization, (b) cardiovascular death, (c) heart failure hospitalization, and (d ) all-cause mortality.
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of LCZ696 on a number of key cardiovascular outcomes, and on
all-cause mortality. Compared in this way, LCZ696 was shown to
have striking effects on all outcomes examined, with the relative risk
reduction for cardiovascular mortality was 32–34% (for cardiovascu-
lar morbidity and mortality it was 39–43%) There were even larger
effects on heart failure hospitalization, with relative risk reductions
of 46–49%. These indirectly estimated effects are convincing
because they were highly statistically significant. They are also highly
clinically relevant as they are similar to the largest effects obtained
when other proven pharmacological therapies were compared dir-
ectly to placebo (i.e. to the effect of beta-blockers on cardiovascular
mortality and MRAs on heart failure hospitalization). Importantly, in
PARADIGM-HF, these benefits were obtained when LCZ696 was
‘added’ to background beta-blocker and MRA therapy.
Although the analytical approach we used is well recognized
and has been employed in regulatory assessments of new drugs, it
relies on certain assumptions that often cannot be met as fully as is
desirable.6 –8 These include the conditions that the placebo-
controlled trial(s) and the active-controlled trial(s) used the same
reference drug and in the same dose, that same outcomes were
evaluated, the populations studied were similar, and that background
therapy did not change between the older and newer trial(s).6– 8,11,12
Only in this way can the effect of the reference compound (in this
case enalapril) against placebo be considered to be constant. Our
analysis meets some but not all of these requirements. We used
the same ACE inhibitor as SOLVD-T, the same dosing-schedule
and achieved a similar average daily dose (16.6 mg SOLVD-T and
18.9 mg in PARADIGM-HF). All the outcomes examined were
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Key baseline characteristics of patients in trials compared
SOLVD-T (n 5 2569) CHARM-Alternative (n 5 2028) PARADIGM-HF (n 5 8399)
Age, years 61 (10) 67 (11) 64 (11)
Female sex, % 20 32 22
NYHA class, %
I 11 0 5
II 57 48 70
III 30 49 24
IV 2 4 1
History
MI 66 61 43
Hypertension 42 50 71
Diabetes mellitus 26 27 35
Systolic BP, mmHg 125 (18) 130 (19) 121 (19)
LVEF, % 25 (7) 30 (7.4) 29 (6.2)
Background therapy (%)
Diuretic 85 85 80
Digoxin 67 45 30
Beta-blocker 8 55 93
MRA NR 24 56
BP, blood pressure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; NR = not
reported.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Number of events and event rates (per 100 patient-years) in trials compared
Outcome number
(ratea)
SOLVD-T CHARM-Alternative PARADIGM-HF
Placebo
(n5 1284)
Enalapril
(n5 1285)
Placebo
(n5 1015)
Candesartan
(n5 1013)
Enalapril
(n 5 4212)
LCZ696
(n5 4187)
CV death or HF
hospitalization
707 (26.2) 573 (18.5) 406 (18.2) 334 (13.8) 1117 (13.2) 914 (10.5)
CV death 461 (13.7) 399 (11.2) 252 (9.8) 219 (8.2) 693 (7.5) 558 (6.0)
HF hospitalization 470 (17.2) 332 (10.9) 286 (12.8) 207 (8.6) 658 (7.7) 537 (6.2)
All-cause mortality 510 (15.1) 452 (12.8) 296 (11.5) 265 (10.0) 835 (9.0) 711 (7.6)
CV, cardiovascular; HF, heart failure.
aRate per 100 patient-years.
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similar although in SOLVD-T the cause of death and hospitalization
was determined by the local site investigator rather than by a
central committee as in CHARM-Alternative and PARADIGM-HF.9
The patients enrolled in PARADIGM-HF and SOLVD-T were
perhaps more similar than might be expected given the 23-year
gap between these trials. However, there were major differences
in background pharmacological therapy between SOLVD-T and
PARADIGM-HF, reflecting the accrualof newevidenceandevolution
of guidelines over that period.13,14 Beta-blocker use was much more
common in PARADIGM-HF and there was probably a similar differ-
ence in MRAuse, althoughwedo notknowforcertain as use ofMRAs
was not reported in SOLVD-T. These differences might raise con-
cerns that we cannot be sure about the constancy of the effect of ena-
lapril. However, CHARM-Alternative provides reassurance in this
respect.10 As documented in Table 3, the effect of candesartan,
compared with placebo, in CHARM-Alternative was qualitatively
Figure2 Putative placebo analysis based upon the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an
angiotensin converting enzyme inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and
morbidity-Alternative trial (CHARM-Alt.) as the reference trial for comparison of an angiotensin receptor blocker to placebo. (A) Composite of
death from cardiovascular causes or heart failure hospitalization, (B) cardiovascular death, (C) heart failure hospitalization, and (D) all-cause
mortality.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Treatment comparisons and hazard ratios for the clinical outcomes analysed
SOLVD-T (n 5 2569) CHARM-Alternative (n 5 2028) PARADIGM-HF (n 5 8399)
Study treatments
Reference treatment Placebo Placebo Enalapril 10 mg bid
Experimental treatment Enalapril 10 mg bid Candesartan 32 mg qd LCZ696 200 mg bid
Clinical outcomes (HR, 95% CI)
CV death or HF hospitalization 0.72 (0.64, 0.80) 0.77 (0.67, 0.89) 0.80 (0.73, 0.87)
CV death 0.83 (0.73, 0.95) 0.85 (0.71, 1.02) 0.80 (0.71, 0.89)
HF hospitalization 0.64 (0.55, 0.73) 0.68 (0.57, 0.81) 0.79 (0.71, 0.89)
All-cause mortality 0.85 (0.75, 0.97) 0.87 (0.74, 1.03) 0.84 (0.76, 0.93)
CV, cardiovascular; HF, heart failure; HR, hazard ratio.
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and quantitatively remarkably similar to the effect of enalapril in
SOLVD-T on all outcomes examined. This was despite the more fre-
quent use of beta-blockers in CHARM-Alternative and probable
greater MRA use as well (and, importantly, the treatment-effect of
candesartan was not modified by either of these background therap-
ies in CHARM-Alternative). In a similar way, CHARM-Alternative
also provides reassurance with respect to the other relatively small
differences in the patient populations enrolled in SOLVD-T and
PARADIGM-HF. This is because the effect of candesartan was
similar to that of enalapril, despite more notable difference
between the characteristics of patients enrolled in CHARM-
Alternative compared with those enrolled in SOLVD-T (and
PARADIGM-HF). This uniformity of treatment-effect makes popula-
tion differences less of a concern. In fact, although a different inhibitor
of the renin–angiotensin system was tested in CHARM-Alternative,
in a somewhat different population which, as mentioned earlier, was
receiving more-contemporary therapy than in SOLVD-T, the puta-
tiveplacebo analysis usingCHARM-Alternative gave very similar find-
ings to the same analytical approach using SOLVD-T. For these
reasons, we believe that our study is as robust as it is possible to be
with analyses of this type.
Although our analysis had the strengths outlined earlier, it also had
the fundamental limitation of all analyses of this type which is that they
are indirect and not direct comparisons. Although early termination
of trials can theoretically overestimate the magnitude of a treatment
effect, we believe that this is unlikely in PARADIGM-HF because
we achieved the projected number of cardiovascular deaths. We
also did not know the proportion of patients in SOLVD-T treated
with an MRA. Only patients intolerant of an ACE inhibitor were en-
rolled in CHARM-Alternative. Conversely, only patients able to tol-
erate enalapril 2.5 mg bid and 10 mg bid were included in SOLVD-T
and in PARADIGM-HF, respectively. In addition, in PARADIGM-HF,
patients switched from established neurohumoral blockade with an
ACE inhibitororARB,whereas inSOLVD-TandCHARM-Alternative
this was not the case. All of these factors create uncertainty about
the exact size of the treatment effect of LCZ696 compared with
placebo and affect the generalizability of our findings. There are
only two large-scale, long-term, ACE inhibitor-placebo or ARB-
placebo comparisons in a broad spectrum of patients with HF-REF.
The duration of follow-up differed between these two trials and
from PARADIGM-HF. We made the assumption that the effect of
LCZ696 compared with enalapril would be the same as that of
LCZ696 compared with candesartan.
In summary, these indirect comparisons of LCZ696 with putative
placebos show that the strategy of combined angiotensin receptor
blockade and neprilysin inhibition leads to striking relative risk reduc-
tions in cardiovascular and all-cause mortality, as well as in heart
failure hospitalization. These estimated benefits were obtained
despite LCZ696 being added to excellent background beta-blocker
and MRA therapy.
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